Zyesami
-
Private Investors Buy $25M in NRx Stock for Radnor Firm’s COVID Research
Undisclosed investors are purchasing 7.8 million shares of NRx Pharmaceutical stock, raising $25 million to finance the Radnor company’s development of therapy and a vaccine…
-
NRx in Radnor Now Seeks Patent for COVID Drug Zyesami, Sees Other Uses
NRx Pharmaceuticals has now added a patent application to its paperwork for the COVID-19 therapy drug Zyesami, writes John George for Philadelphia Business Journal. Earlier…
-
NRx in Radnor Asks Again for Approval to Use Its COVID-19 Drug, Zyesami
NRx Pharmaceuticals out of Radnor has once again filed an application with the Food and Drug Administration for emergency use of its experimental COVID-19 drug…
-
Promising Results From COVID Drug Pushes Up Radnor Pharm’s Stock
Patients treated with an NRx Pharmaceuitcals drug candidate targeting COVID-19 showed “substantial improvement,” an analysis shows. The news caused the Radnor company’s stock to…
-
NRx in Radnor Has Stock Sale to Raise Funds for COVID Drug, Vaccine Research
A Radnor pharmaceutical company , NRx, active in COVID-19 research is entering into a multi-million dollar private stock sale, writes John George for Philadelphia Business…
-
NRx in Radnor Cleared to Use Its COVID-19 Drug in Country of Georgia
With COVID-19 cases growing by 1,000 cases a day, the country of Georgia has issued an emergency authorization to use a COVID-19 therapy, Zyesami, developed…
Founding Partners
Advertisement
Affiliate Partners
Chamber Partners
